As Dex or Vitamin D receptor agonists have been described to generate tolDCs through NF-κB down-regulation, it is possible that well-controlled patients have a better capacity to overcome sustained hyperglycemia driven NF-κB activation in the process of tolDCs generation. Here, NFKB1 is linked to Hyperglycemia.